12P Stromal CD73 expression in early-stage high-risk luminal B-like breast cancer: An exploratory analysis from the randomized Neo-CheckRay trial
CD73 catalyzes the conversion of ATP into immunosuppressive adenosine in the tumor microenvironment. Stromal CD73 may modulate anti-tumor immunity and influence therapy response. We examined stromal CD73 expression and its associations with clinical features, immune biomarkers, and pathological complete response (pCR) at surgery in early-stage, high-risk luminal B-like breast cancer patients from the randomized Neo-CheckRay trial (NCT03875573).
Authors
- J. Dhont
- E. Romano
- C. Sotiriou
- X. Catteau
- A. De Caluwe
- L. Buisseret
- M. Carausu
- Z. Denis
- T. Yin
- J. Stagg
- F. Lifrange
Institutions
- Université Libre de Bruxelles (BE)
- Institut Jules Bordet (BE)
- Université de Montréal (CA)
- Institut Curie (FR)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101097
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00